Sabril®
Pre-clinicalCompleted 0 views this week 0 watching💤 Quiet
Interest: 23/100
23
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Infantile Spasms
Conditions
Infantile Spasms, Refractory Complex Partial Seizures in Adults
Trial Timeline
Aug 1, 2009 → —
NCT ID
NCT01073579About Sabril®
Sabril® is a pre-clinical stage product being developed by Lundbeck for Infantile Spasms. The current trial status is completed. This product is registered under clinical trial identifier NCT01073579. Target conditions include Infantile Spasms, Refractory Complex Partial Seizures in Adults.
What happened to similar drugs?
3 of 7 similar drugs in Infantile Spasms were approved
Approved (3) Terminated (2) Active (4)
Hype Score Breakdown
Clinical
3
Activity
8
Company
12
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01073579 | Pre-clinical | Completed |
Competing Products
16 competing products in Infantile Spasms
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| TSHA-101 | Taysha Gene Therapies | Phase 1/2 | 30 |
| MAS825 + Placebo | Novartis | Phase 2 | 39 |
| alglucosidase alfa + alglucosidase alfa | Sanofi | Approved | 35 |
| Myozyme | Sanofi | Phase 2 | 35 |
| Bacillus Clausii Multi ATB Resist + Placebo | Sanofi | Approved | 43 |
| Radiprodil | UCB | Phase 2 | 27 |
| Larotrectinib (Vitrakvi, BAY2757556) + Standard of Care | Bayer | Pre-clinical | 23 |
| Vigabatrin | Lundbeck | Approved | 32 |
| Nusinersen | Biogen | Pre-clinical | 23 |
| GWP42003-P | Jazz Pharmaceuticals | Phase 3 | 37 |
| GWP42003-P | Jazz Pharmaceuticals | Phase 3 | 37 |
| Cerliponase Alfa | BioMarin Pharmaceutical | Pre-clinical | 27 |
| Cholic Acids | Mirum Pharmaceuticals | Phase 3 | 37 |
| Cipaglucosidase alfa + Miglustat | Amicus Therapeutics | Phase 3 | 44 |
| ATB200 + AT2221 | Amicus Therapeutics | Pre-clinical | 27 |
| RP-L401 | Rocket Pharmaceuticals | Phase 1 | 11 |